Treatment of basal cell skin cancer in 2016: Tips and techniques

Eyal Levit
Advanced Dermatology Laser and Cosmetic Surgery, USA

Recent advances in the treatment of Basal Cell Skin Cancer (BCC) have targeted the PATCH gene mutation found in up to 80% of BCCs. The reported cure rate of these biological therapies is about 40%. The difficulty of these treatments is preventing the recurrence of the tumor once the biological therapy is discontinued. Current and new treatment options for skin cancer with their potential risks and benefits will be presented as well as a novel treatment modality utilizing the combination therapies of Imiquimod cream and Vismodegib to improve the cure rate to about 90%. A successfully cured case of a large BCC using Vismodigib and Imiquimod will be reviewed suggesting a promising path for non-surgical solution of BCC in selected cases.

Biography

Eyal Levit has completed his MD at the Albert Einstein College of Medicine in 1995. He has completed his Dermatology Residency at Columbia Presbyterian Medical Center. Following his Residency he has completed a one year MOHS Micrographic, Laser and Dermatologic Surgery Fellowship at the University of Pennsylvania, USA. He had an additional 2 years of Fellowship training in Cosmetic and Laser Surgery at Columbia University. Until recently he was the Director of Cosmetic and Dermatologic Surgery at St. Luke’s Hospital Columbia University, a post he held for 14 years. He currently runs an Advanced Dermatology Laser and Cosmetic Surgery, a thriving dermatology practice in New York City. He has published over 20 papers and is a recipient of multiple awards.

Notes: